Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | FAAH | O00519 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.46 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029653 | 0.93 | CASP2 (0.51) | CASP2NAAAEPHX1DNM1FAAH | |
| SCHEMBL9655480 | 0.93 | CASP2 (0.51) | CASP2NAAAEPHX1DNM1FAAH | |
| SCHEMBL1420133 | 0.93 | CASP2 (0.51) | CASP2NAAAEPHX1DNM1FAAH | |
| SCHEMBL1419852 | 0.93 | CASP2 (0.51) | CASP2NAAAEPHX1DNM1FAAH | |
| SCHEMBL1419475 | 0.93 | CASP2 (0.51) | CASP2NAAAEPHX1DNM1FAAH | |
| SCHEMBL1419840 | 0.93 | CASP2 (0.51) | CASP2NAAAEPHX1DNM1FAAH | |
| SCHEMBL2029786 | 0.93 | CASP2 (0.51) | CASP2NAAAEPHX1DNM1FAAH | |
| SCHEMBL1419654 | 0.93 | CASP2 (0.51) | CASP2NAAAEPHX1DNM1FAAH | |
| SCHEMBL2027019 | 0.93 | CASP2 (0.51) | CASP2NAAAEPHX1DNM1FAAH | |
| SCHEMBL1419815 | 0.93 | CASP2 (0.51) | CASP2NAAAEPHX1DNM1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-06-08 | — | — | US | disclosed |
| US-20200361854-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-19 | — | — | US | disclosed |
| US-20180065918-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-08 | — | — | US | disclosed |
| US-9663449-B2 | — | — | 2017-05-30 | — | — | US | disclosed |
| EP-2695608-B1 | Lipid containing formulations | ARBUTUS BIOPHARMA CORP (CA) | 2016-11-23 | — | — | EP | disclosed |
| US-20140121393-A1 | LIPID CONTAINING FORMULATIONS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-05-01 | — | — | US | disclosed |
| US-8034376-B2 | Lipid containing formulations | Alnylam Pharamaceticals, Inc. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | BANK OF AMERICA, N.A. | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361854-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CASP2 3881/4885NAAA 1445/4885EPHX1 3072/4885 |
| US-20180065918-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CASP2 3881/4885NAAA 1445/4885EPHX1 3072/4885 |
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CASP2 3881/4885NAAA 1445/4885EPHX1 3072/4885 |
| US-20140121393-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CASP2 3881/4885NAAA 1445/4885EPHX1 3072/4885 |
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CASP2 3881/4885NAAA 1445/4885EPHX1 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.